Thioglycosides Are Efficient Metabolic Decoys of Glycosylation that Reduce Selectin Dependent Leukocyte Adhesion

© 2018 Elsevier Ltd Small-molecule inhibitors of glycosylation can be applied in basic science studies, and clinical investigations as anti-inflammatory, anti-metastatic, and anti-viral therapies. This article demonstrates that thioglycosides represent a class of potent metabolic decoys that resist hydrolysis, and block E-selectin-dependent leukocyte adhesion in models of inflammation

Time-Energy Uncertainty Relations for Neutrino Oscillation and M\"Ossbauer Neutrino Experiment

Using the Mandelstam-Tamm method we derive time-energy uncertainty relations for neutrino oscillations. We demonstrate that the small energy uncertainty of antineutrinos in a recently considered experiment with recoilless resonant (M\"ossbauer) production and absorption of tritium antineutrinos is in conflict with the energy uncertainty which, according to the time-energy uncertainty relation, is necessary for neutrino oscillations to happen. A M\"ossbauer neutrino experiment could provide a unique possibility to test the applicability of the time-energy uncertainty relation to neutrino oscillations and to reveal the true nature of neutrino oscillations

Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"

No abstract availabl

Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis

Objective A major challenge in multiple sclerosis (MS) research is the understanding of silent progression and Progressive MS. Using a novel method to accurately capture upper cervical cord area from legacy brain MRI scans we aimed to study the role of spinal cord and brain atrophy for silent progression and conversion to secondary progressive disease (SPMS). Methods From a single-center observational study, all RRMS (n = 360) and SPMS (n = 47) patients and 80 matched controls were evaluated. RRMS patient subsets who converted to SPMS (n = 54) or silently progressed (n = 159), respectively, during the 12-year observation period were compared to clinically matched RRMS patients remaining RRMS (n = 54) or stable (n = 147), respectively. From brain MRI, we assessed the value of brain and spinal cord measures to predict silent progression and SPMS conversion. Results Patients who developed SPMS showed faster cord atrophy rates (-2.19%/yr) at least 4 years before conversion compared to their RRMS matches (-0.88%/yr, p < 0.001). Spinal cord atrophy rates decelerated after conversion (-1.63%/yr, p = 0.010) towards those of SPMS patients from study entry (-1.04%). Each 1% faster spinal cord atrophy rate was associated with 69% (p < 0.0001) and 53% (p < 0.0001) shorter time to silent progression and SPMS conversion, respectively. Interpretation Silent progression and conversion to secondary progressive disease are predominantly related to cervical cord atrophy. This atrophy is often present from the earliest disease stages and predicts the speed of silent progression and conversion to Progressive MS. Diagnosis of SPMS is rather a late recognition of this neurodegenerative process than a distinct disease phase. ANN NEUROL 202

Nanoscopic building blocks from polymers, metals, and semiconductors for hybrid architectures

10.1142/S0218863504001815Journal of Nonlinear Optical Physics and Materials132229-24